VectorBuilder Redefines Plasmid Standards with miniVec
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Subscribe To Our Newsletter & Stay Updated